Abstract
Malaria is the world’s most fatal disease - causing up to 2.7 million deaths annually all over the world. The ability of organisms to develop resistance against existing antimalarial drugs exacerbates the problem. There is a clear cut need for more effective, affordable and accessible drugs that act by novel modes of action. Glutathione synthetase (GS) from Plasmodium falciparum represents an important potential drug target due to its defensive role; hence ceasing the respective metabolic step will destroy the parasite. A three dimensional model of Plasmodium GS was constructed by de novo modelling method and potential GS inhibitors were identified from a library of glutathione (GSH) analogues retrieved from Ligand-info database and filtered using Lipinski and ADME rules. Two common feature pharmacophore models were generated from the individual inhibitor clusters to provide insight into the key pharmacophore features that are crucial for the GS inhibition. Molecular docking of selective compounds into the predicted GS binding site revealed that the compound CMBMB was the best GS inhibitor when compared to the standard reference Chloroquine (CQ). This was taken as indicating that CMBMB was the best effective and safest drug against P. falciparum.
Keywords: ADME, drug targets, Glutathione synthetase, molecular docking, P. falciparum, pharmacophore.
Combinatorial Chemistry & High Throughput Screening
Title:Screening and Identification of Inhibitors Against Glutathione Synthetase, A Potential Drug Target of Plasmodium falciparum
Volume: 18 Issue: 5
Author(s): Yellapu Nanda Kumar, Gopal Jeyakodi, Ramamoorthy Thulasibabu, Kasinathan Gunasekaran and Purushothaman Jambulingam
Affiliation:
Keywords: ADME, drug targets, Glutathione synthetase, molecular docking, P. falciparum, pharmacophore.
Abstract: Malaria is the world’s most fatal disease - causing up to 2.7 million deaths annually all over the world. The ability of organisms to develop resistance against existing antimalarial drugs exacerbates the problem. There is a clear cut need for more effective, affordable and accessible drugs that act by novel modes of action. Glutathione synthetase (GS) from Plasmodium falciparum represents an important potential drug target due to its defensive role; hence ceasing the respective metabolic step will destroy the parasite. A three dimensional model of Plasmodium GS was constructed by de novo modelling method and potential GS inhibitors were identified from a library of glutathione (GSH) analogues retrieved from Ligand-info database and filtered using Lipinski and ADME rules. Two common feature pharmacophore models were generated from the individual inhibitor clusters to provide insight into the key pharmacophore features that are crucial for the GS inhibition. Molecular docking of selective compounds into the predicted GS binding site revealed that the compound CMBMB was the best GS inhibitor when compared to the standard reference Chloroquine (CQ). This was taken as indicating that CMBMB was the best effective and safest drug against P. falciparum.
Export Options
About this article
Cite this article as:
Kumar Nanda Yellapu, Jeyakodi Gopal, Thulasibabu Ramamoorthy, Gunasekaran Kasinathan and Jambulingam Purushothaman, Screening and Identification of Inhibitors Against Glutathione Synthetase, A Potential Drug Target of Plasmodium falciparum, Combinatorial Chemistry & High Throughput Screening 2015; 18 (5) . https://dx.doi.org/10.2174/138620731805150722165639
DOI https://dx.doi.org/10.2174/138620731805150722165639 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Role of Rho-Associated Protein Kinase Inhibitors for Glaucoma Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Systems Biology of HBOC-Induced Vasoconstriction
Current Drug Discovery Technologies SRC-3/AIB-1 may Enhance Hepatic NFATC1 Transcription and Mediate Inflammation in a Tissue-Specific Manner in Morbid Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Impact of Nutrients on the Functioning of Intestinal Goblet Cells: Health and Therapeutic Perspectives
Current Nutrition & Food Science Microemulsions: A Novel Approach to Enhanced Drug Delivery
Recent Patents on Drug Delivery & Formulation Tumor Stem Cell Niches: A New Functional Framework for the Action of Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery 2,4,6-Trichlorophenylhydrazine Schiff Bases as DPPH Radical and Super Oxide Anion Scavengers
Medicinal Chemistry Hypertension in Pregnancy: A Review of Current Guidelines
Current Women`s Health Reviews Development of Repaglinide Loaded Solid Lipid Nanocarrier: Selection of Fabrication Method
Current Drug Delivery Prediction of Protein Signal Sequences
Current Protein & Peptide Science Dietary Additive Probiotics Modulation of the Intestinal Microbiota
Protein & Peptide Letters Medulloblastoma: Role of Developmental Pathways, DNA Repair Signaling, and Other Players
Current Molecular Medicine TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry Epidemiology of Severe Sepsis Around the World
Endocrine, Metabolic & Immune Disorders - Drug Targets Breastfeeding Policy Development and the Prevention of Obesity
Current Pediatric Reviews Role of Quality Management System (QMS) for Effective Regulatory Compliance
Applied Clinical Research, Clinical Trials and Regulatory Affairs Genome Study of Kidney Disease in the Age of Post Genome-Sequencing
Endocrine, Metabolic & Immune Disorders - Drug Targets Fabricating Tissue Engineering Scaffolds for Simultaneous Cell Growth and Drug Delivery
Current Pharmaceutical Design Trehalose Protects against Insulin Resistance-Induced Tissue Injury and Excessive Autophagy in Skeletal Muscles and Kidney
Current Pharmaceutical Design Overdoses of Acetaminophen Disrupt the Thyroid-Liver Axis in Neonatal Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets